Friday 6 November 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024.
- Revenue
- +1.73%
- EPS
- +40.7%
- Free cash flow
- −41.3%
- Total debt
- +2.45%
Quarter to June 2026, against a year earlier
3.26
0.27
−7.65%
Follow TLSI
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 4 | 4 |
| 306.43% | 238.03% | 542.50% | 911.60% | ||
| (226.01%) | (239.84%) | (117.45%) | (113.09%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(298.03%) | (315.33%) | (100.34%) | (116.40%) | |
Average Days of Receivables |
45.39 | 53.01 | 42.41 | 52.30 | |
Free Cash Flow per Share |
(0.51) | (0.50) | (0.39) | (0.40) | |
Free Cash Flow |
(22.08) | (18.85) | (20.26) | (23.24) | |
Capital Expenditures |
(0.85) | (0.84) | (0.26) | (0.44) | |
| Other line items | |||||
Cash ROIC |
(76.87%) | (96.06%) | (19.78%) | (27.06%) | |
Accounts Receivable Turnover |
8.11 | 7.75 | 8.41 | 7.49 | |
Accounts Payable Turnover |
2.45 | 2.64 | 1.90 | 2.26 | |
Inventory Turnover |
1.76 | 1.96 | 1.69 | 1.60 | |
Average Days of Payables |
215.17 | 157.32 | 230.55 | 214.41 | |
Days of Inventory on Hand |
186.28 | 161.25 | 205.82 | 239.59 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
36.87% | 33.14% | 33.78% | 32.45% | |
Selling, General and Administrative Expense of Revenue |
124.90% | 111.11% | 113.74% | 121.02% | |
Share Based Compensation of Revenue |
21.47% | 20.22% | 22.24% | 23.75% | |
Interest Coverage |
(6.06) | (4.86) | (4.86) | (5.23) | |
Operating CF/Net income |
0.29 | 0.25 | 0.34 | 0.39 | |
Depreciation/Fixed assets |
0.90 | 0.93 | 0.87 | 0.95 | |
Capex/Depreciation |
(0.52) | (0.50) | (0.16) | (0.25) | |
Revenue per Share |
0.93 | 1.19 | 0.87 | 0.77 | |
Operating CF per Share |
(0.49) | (0.48) | (0.39) | (0.39) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 25 Oct 2026